In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avib...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	James A. Karlowsky, Krystyna M. Kazmierczak, Maria Lavínea Novis de Figueiredo Valente, Elkin Lemos Luengas, Monique Baudrit, Alvaro Quintana, Paurus Irani, Gregory G. Stone, Daniel F. Sahm
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Ceftazidime-avibactam Latin America Surveillance Gram-negative Enterobacterales Pseudomonas aeruginosa Infectious and parasitic diseases RC109-216 Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/0a60f6b6ac304f39b06d01229151dcd9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a60f6b6ac304f39b06d01229151dcd9
record_format	dspace
spelling	oai:doaj.org-article:0a60f6b6ac304f39b06d01229151dcd92021-11-30T04:14:33ZIn vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–20191413-867010.1016/j.bjid.2021.101647https://doaj.org/article/0a60f6b6ac304f39b06d01229151dcd92021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1413867021001161https://doaj.org/toc/1413-8670The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avibactam and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Overall, 98.1% of Enterobacterales and 86.9% of P. aeruginosa isolates were susceptible to ceftazidime-avibactam. When isolates were analyzed by country of origin, susceptibility to ceftazidime-avibactam for Enterobacterales ranged from 97.8% to 100% for nine of 10 countries (except Guatemala, 86.3% susceptible) and from 75.9% to 98.4% for P. aeruginosa in all 10 countries. For Enterobacterales, 100% of AmpC-positive, ESBL- and AmpC-positive, GES-type carbapenemase-positive, and OXA-48-like-positive isolates were ceftazidime-avibactam-susceptible as were 99.8%, 91.8%, and 74.7% of ESBL-positive, multidrug-resistant (MDR), and meropenem-nonsusceptible isolates. Among meropenem-nonsusceptible isolates of Enterobacterales, 24.4% (139/570) carried a metallo-β-lactamase (MBL); 83.3% of the remaining meropenem-nonsusceptible isolates carried another class of carbapenemase and 99.4% of those isolates were ceftazidime-avibactam-susceptible. Among meropenem-non-susceptible isolates of P. aeruginosa (n = 835), 25.6% carried MBLs; no acquired β-lactamase was identified in the majority of isolates (64.8%; 87.2% of those isolates were ceftazidime-avibactam-susceptible). Overall, clinical isolates of Enterobacterales collected in Latin America from 2017 to 2019 were highly susceptible to ceftazidime-avibactam, including isolates carrying ESBLs, AmpCs, and KPCs. Country-specific variation in susceptibility to ceftazidime-avibactam was more common among isolates of P. aeruginosa than Enterobacterales. The frequency of MBL-producers among Enterobacterales from Latin America was low (1.7% of all isolates; 146/8,416), but higher than reported in previous surveillance studies.James A. KarlowskyKrystyna M. KazmierczakMaria Lavínea Novis de Figueiredo ValenteElkin Lemos LuengasMonique BaudritAlvaro QuintanaPaurus IraniGregory G. StoneDaniel F. SahmElsevierarticleCeftazidime-avibactamLatin AmericaSurveillanceGram-negativeEnterobacteralesPseudomonas aeruginosaInfectious and parasitic diseasesRC109-216MicrobiologyQR1-502ENBrazilian Journal of Infectious Diseases, Vol 25, Iss 6, Pp 101647- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ceftazidime-avibactam Latin America Surveillance Gram-negative Enterobacterales Pseudomonas aeruginosa Infectious and parasitic diseases RC109-216 Microbiology QR1-502
spellingShingle	Ceftazidime-avibactam Latin America Surveillance Gram-negative Enterobacterales Pseudomonas aeruginosa Infectious and parasitic diseases RC109-216 Microbiology QR1-502 James A. Karlowsky Krystyna M. Kazmierczak Maria Lavínea Novis de Figueiredo Valente Elkin Lemos Luengas Monique Baudrit Alvaro Quintana Paurus Irani Gregory G. Stone Daniel F. Sahm In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
description	The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avibactam and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Overall, 98.1% of Enterobacterales and 86.9% of P. aeruginosa isolates were susceptible to ceftazidime-avibactam. When isolates were analyzed by country of origin, susceptibility to ceftazidime-avibactam for Enterobacterales ranged from 97.8% to 100% for nine of 10 countries (except Guatemala, 86.3% susceptible) and from 75.9% to 98.4% for P. aeruginosa in all 10 countries. For Enterobacterales, 100% of AmpC-positive, ESBL- and AmpC-positive, GES-type carbapenemase-positive, and OXA-48-like-positive isolates were ceftazidime-avibactam-susceptible as were 99.8%, 91.8%, and 74.7% of ESBL-positive, multidrug-resistant (MDR), and meropenem-nonsusceptible isolates. Among meropenem-nonsusceptible isolates of Enterobacterales, 24.4% (139/570) carried a metallo-β-lactamase (MBL); 83.3% of the remaining meropenem-nonsusceptible isolates carried another class of carbapenemase and 99.4% of those isolates were ceftazidime-avibactam-susceptible. Among meropenem-non-susceptible isolates of P. aeruginosa (n = 835), 25.6% carried MBLs; no acquired β-lactamase was identified in the majority of isolates (64.8%; 87.2% of those isolates were ceftazidime-avibactam-susceptible). Overall, clinical isolates of Enterobacterales collected in Latin America from 2017 to 2019 were highly susceptible to ceftazidime-avibactam, including isolates carrying ESBLs, AmpCs, and KPCs. Country-specific variation in susceptibility to ceftazidime-avibactam was more common among isolates of P. aeruginosa than Enterobacterales. The frequency of MBL-producers among Enterobacterales from Latin America was low (1.7% of all isolates; 146/8,416), but higher than reported in previous surveillance studies.
format	article
author	James A. Karlowsky Krystyna M. Kazmierczak Maria Lavínea Novis de Figueiredo Valente Elkin Lemos Luengas Monique Baudrit Alvaro Quintana Paurus Irani Gregory G. Stone Daniel F. Sahm
author_facet	James A. Karlowsky Krystyna M. Kazmierczak Maria Lavínea Novis de Figueiredo Valente Elkin Lemos Luengas Monique Baudrit Alvaro Quintana Paurus Irani Gregory G. Stone Daniel F. Sahm
author_sort	James A. Karlowsky
title	In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
title_short	In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
title_full	In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
title_fullStr	In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
title_full_unstemmed	In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
title_sort	in vitro activity of ceftazidime-avibactam against enterobacterales and pseudomonas aeruginosa isolates collected in latin america as part of the atlas global surveillance program, 2017–2019
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/0a60f6b6ac304f39b06d01229151dcd9
work_keys_str_mv	AT jamesakarlowsky invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT krystynamkazmierczak invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT marialavineanovisdefigueiredovalente invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT elkinlemosluengas invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT moniquebaudrit invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT alvaroquintana invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT paurusirani invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT gregorygstone invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT danielfsahm invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019
_version_	1718406785151270912

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

Ejemplares similares